{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:17:25Z","timestamp":1722212245556},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,28]]},"DOI":"10.7759\/cureus.65579","type":"journal-article","created":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T14:41:27Z","timestamp":1722177687000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-World Clinical Profile and Safety of Nintedanib in Systemic Sclerosis-Associated Interstitial Lung Disease: A Subgroup Analysis of Interstitial Lung Disease Data From an Interstitial Lung Disease (ILD) Specialty Clinic in India"],"prefix":"10.7759","author":[{"given":"Ajoy K","family":"Behera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pratibha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranganath","family":"TG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikas","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saroj  K","family":"Pati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kulshreshth","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00073012","article-title":"The pathogenesis of pulmonary fibrosis: a moving target","volume":"41","author":"Wuyts WA","year":"2013","unstructured":"Wuyts WA, Agostini C, Antoniou KM, et al.. The pathogenesis of pulmonary fibrosis: a moving target. Eur Respir J. 2013, 41:1207-18. 10.1183\/09031936.00073012","journal-title":"Eur Respir J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201903-0486OC","article-title":"Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort","volume":"200","author":"Hoffmann-Vold AM","year":"2019","unstructured":"Hoffmann-Vold AM, Fretheim H, Halse AK, et al.. Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort. Am J Respir Crit Care Med. 2019, 200:1258-66. 10.1164\/rccm.201903-0486OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S191418","article-title":"Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease","volume":"11","author":"Bergamasco A","year":"2019","unstructured":"Bergamasco A, Hartmann N, Wallace L, Verpillat P. Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease. Clin Epidemiol. 2019, 11:257-73. 10.2147\/CLEP.S191418","journal-title":"Clin Epidemiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30144-4","article-title":"The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements","volume":"2","author":"Hoffmann-Vold AM","year":"2020","unstructured":"Hoffmann-Vold AM, Maher TM, Philpot EE, et al.. The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. Lancet Rheumatol. 2020, 2:71-83. 10.1016\/S2665-9913(19)30144-4","journal-title":"Lancet Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2014.12.005","article-title":"Interstitial lung disease in scleroderma","volume":"41","author":"Schoenfeld SR","year":"2015","unstructured":"Schoenfeld SR, Castelino FV. Interstitial lung disease in scleroderma. Rheum Dis Clin North Am. 2015, 41:237-48. 10.1016\/j.rdc.2014.12.005","journal-title":"Rheum Dis Clin North Am"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.096677","article-title":"EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)","volume":"68","author":"Kowal-Bielecka O","year":"2009","unstructured":"Kowal-Bielecka O, Landew\u00e9 R, Avouac J, et al.. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009, 68:620-8. 10.1136\/ard.2008.096677","journal-title":"Ann Rheum Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler O","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M, et al.. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019, 380:2518-28. 10.1056\/NEJMoa1903076","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202306-1113ST","article-title":"Treatment of systemic sclerosis-associated interstitial lung disease: evidence-based recommendations. An Official American Thoracic Society Clinical Practice Guideline","volume":"209","author":"Raghu G","year":"2024","unstructured":"Raghu G, Montesi SB, Silver RM, et al.. Treatment of systemic sclerosis-associated interstitial lung disease: evidence-based recommendations. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2024, 209:137-52. 10.1164\/rccm.202306-1113ST","journal-title":"Am J Respir Crit Care Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/art.22532","article-title":"Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors","volume":"57","author":"McNearney TA","year":"2007","unstructured":"McNearney TA, Reveille JD, Fischbach M, et al.. Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum. 2007, 57:318-26. 10.1002\/art.22532","journal-title":"Arthritis Rheum"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society technical statement","volume":"200","author":"Graham BL","year":"2019","unstructured":"Graham BL, Steenbruggen I, Miller MR, et al.. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society technical statement. Am J Respir Crit Care Med. 2019, 200:e70-88. 10.1164\/rccm.201908-1590ST","journal-title":"Am J Respir Crit Care Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: guidelines for the six-minute walk test","volume":"166","year":"2002","unstructured":"ATS statement. guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002, 166:111-7. 10.1164\/ajrccm.166.1.at1102","journal-title":"Am J Respir Crit Care Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2018-000363","article-title":"The King's Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference","volume":"6","author":"Sinha A","year":"2019","unstructured":"Sinha A, Patel AS, Siegert RJ, et al.. The King's Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference. BMJ Open Respir Res. 2019, 6:e000363. 10.1136\/bmjresp-2018-000363","journal-title":"BMJ Open Respir Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00035005","article-title":"Standardisation of the measurement of lung volumes","volume":"26","author":"Wanger J","year":"2005","unstructured":"Wanger J, Clausen JL, Coates A, et al.. Standardisation of the measurement of lung volumes. Eur Respir J. 2005, 26:511-22. 10.1183\/09031936.05.00035005","journal-title":"Eur Respir J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/art.38390","article-title":"Prediction of pulmonary complications and long-term survival in systemic sclerosis","volume":"66","author":"Nihtyanova SI","year":"2014","unstructured":"Nihtyanova SI, Schreiber BE, Ong VH, et al.. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol. 2014, 66:1625-35. 10.1002\/art.38390","journal-title":"Arthritis Rheumatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0210-2022","article-title":"Prevalence, imaging patterns and risk factors of interstitial lung disease in connective tissue disease: a systematic review and meta-analysis","volume":"32","author":"Joy GM","year":"2023","unstructured":"Joy GM, Arbiv OA, Wong CK, et al.. Prevalence, imaging patterns and risk factors of interstitial lung disease in connective tissue disease: a systematic review and meta-analysis. Eur Respir Rev. 2023, 32:220210. 10.1183\/16000617.0210-2022","journal-title":"Eur Respir Rev"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.111106","article-title":"Epidemiology of systemic sclerosis in a large US managed care population","volume":"39","author":"Furst DE","year":"2012","unstructured":"Furst DE, Fernandes AW, Iorga SR, Greth W, Bancroft T. Epidemiology of systemic sclerosis in a large US managed care population. J Rheumatol. 2012, 39:784-6. 10.3899\/jrheum.111106","journal-title":"J Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02026-2019","article-title":"Predictors of progression in systemic sclerosis patients with interstitial lung disease","volume":"55","author":"Distler O","year":"2020","unstructured":"Distler O, Assassi S, Cottin V, et al.. Predictors of progression in systemic sclerosis patients with interstitial lung disease. Eur Respir J. 2020, 55:10.1183\/13993003.02026-2019","journal-title":"Eur Respir J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes076","article-title":"Prevalence of systemic sclerosis in south-east Norway","volume":"51","author":"Hoffmann-Vold AM","year":"2012","unstructured":"Hoffmann-Vold AM, Midtvedt \u00d8, Molberg \u00d8, Garen T, Gran JT. Prevalence of systemic sclerosis in south-east Norway. Rheumatology (Oxford). 2012, 51:1600-5. 10.1093\/rheumatology\/kes076","journal-title":"Rheumatology (Oxford)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-019-0943-2","article-title":"Demographic and clinical predictors of progression and mortality in connective tissue disease-associated interstitial lung disease: a retrospective cohort study","volume":"19","author":"Chan C","year":"2019","unstructured":"Chan C, Ryerson CJ, Dunne JV, Wilcox PG. Demographic and clinical predictors of progression and mortality in connective tissue disease-associated interstitial lung disease: a retrospective cohort study. BMC Pulm Med. 2019, 19:192. 10.1186\/s12890-019-0943-2","journal-title":"BMC Pulm Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41431-018-0104-8","article-title":"Genetic predictors of systemic sclerosis-associated interstitial lung disease: a review of recent literature","volume":"26","author":"Stock CJ","year":"2018","unstructured":"Stock CJ, Renzoni EA. Genetic predictors of systemic sclerosis-associated interstitial lung disease: a review of recent literature. Eur J Hum Genet. 2018, 26:765-77. 10.1038\/s41431-018-0104-8","journal-title":"Eur J Hum Genet"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead234","article-title":"Prognostic and predictive markers of systemic sclerosis-associated interstitial lung disease\u00a0in a clinical trial and long-term observational cohort","volume":"63","author":"Ghuman A","year":"2024","unstructured":"Ghuman A, Khanna D, Lin CJ, et al.. Prognostic and predictive markers of systemic sclerosis-associated interstitial lung disease\u00a0in a clinical trial and long-term observational cohort. Rheumatology (Oxford). 2024, 63:472-81. 10.1093\/rheumatology\/kead234","journal-title":"Rheumatology (Oxford)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2022.102211","article-title":"Current advances in the treatment of systemic sclerosis","volume":"64","author":"Bukiri H","year":"2022","unstructured":"Bukiri H, Volkmann ER. Current advances in the treatment of systemic sclerosis. Curr Opin Pharmacol. 2022, 64:102211. 10.1016\/j.coph.2022.102211","journal-title":"Curr Opin Pharmacol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin DP","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ, et al.. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006, 354:2655-66. 10.1056\/NEJMoa055120","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/art.22204","article-title":"A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma","volume":"54","author":"Hoyles RK","year":"2006","unstructured":"Hoyles RK, Ellis RW, Wellsbury J, et al.. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006, 54:3962-70. 10.1002\/art.22204","journal-title":"Arthritis Rheum"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin DP","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ, et al.. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016, 4:708-19. 10.1016\/S2213-2600(16)30152-7","journal-title":"Lancet Respir Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30330-1","article-title":"Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial","volume":"9","author":"Highland KB","year":"2021","unstructured":"Highland KB, Distler O, Kuwana M, et al.. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet Respir Med. 2021, 9:96-106. 10.1016\/S2213-2600(20)30330-1","journal-title":"Lancet Respir Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/259650-real-world-clinical-profile-and-safety-of-nintedanib-in-systemic-sclerosis-associated-interstitial-lung-disease-a-subgroup-analysis-of-interstitial-lung-disease-data-from-an-interstitial-lung-disease-ild-specialty-clinic-in-india","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T14:41:30Z","timestamp":1722177690000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/259650-real-world-clinical-profile-and-safety-of-nintedanib-in-systemic-sclerosis-associated-interstitial-lung-disease-a-subgroup-analysis-of-interstitial-lung-disease-data-from-an-interstitial-lung-disease-ild-specialty-clinic-in-india"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,28]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.65579","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,28]]}}}